A Study Of CP-690,550 In Stable Kidney Transplant Patients
Public ClinicalTrials.gov record NCT01710033. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1, Placebo-controlled, Randomized, Sequential, Parallel-group, Dose Escalation Study to Evaluate 28-day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-690,550 in Stable Renal Allograft Recipients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients. In Stage 1, ascending doses of CP-690,550 were to be administered sequentially to 3-4 cohorts of subjects. After Stage 1, one dose level was to be selected for dosing in an expanded cohort in Stage 2.
Study identification
- NCT ID
- NCT01710033
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- CP-690,550 5 mg BID Drug
- CP-690,550 15 mg BID Drug
- CP-690,550 30 mg BID Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2003
- Primary completion
- Mar 31, 2005
- Completion
- Mar 31, 2005
- Last update posted
- Dec 25, 2012
2003 – 2005
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35249-6860 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35249 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294-6862 | — |
| Pfizer Investigational Site | Los Angeles | California | 90057 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46202 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55404 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110-1092 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110-1093 | — |
| Pfizer Investigational Site | Livingston | New Jersey | 07039 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01710033, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 25, 2012 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01710033 live on ClinicalTrials.gov.